{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+hydration",
    "query": {
      "intervention": "Oral hydration"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+hydration&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T11:20:10.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01093131",
      "title": "Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contrast Induced Nephropathy"
      ],
      "interventions": [
        {
          "name": "Oral hydration",
          "type": "OTHER"
        },
        {
          "name": "Oral sodium bicarbonate",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Hydration",
          "type": "OTHER"
        },
        {
          "name": "Intravenous sodium bicarbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "The Western Pennsylvania Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2005-02",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093131"
    },
    {
      "nct_id": "NCT05428774",
      "title": "Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fluid Retention",
        "Beverage Hydration Index",
        "Hydration Status"
      ],
      "interventions": [
        {
          "name": "Test product 1",
          "type": "OTHER"
        },
        {
          "name": "Test product 2",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Liquid I.V.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2022-08-01",
      "completion_date": "2023-01-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-25",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05428774"
    },
    {
      "nct_id": "NCT06645431",
      "title": "Effect of Low Water Intake on Glucose Regulation Measured Using Continuous Glucose Monitoring",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Glucose Concentration",
        "Blood Glucose Self Monitoring"
      ],
      "interventions": [
        {
          "name": "Water Intake",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "California Polytechnic State University-San Luis Obispo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-10-01",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "San Luis Obispo, California",
      "locations": [
        {
          "city": "San Luis Obispo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06645431"
    },
    {
      "nct_id": "NCT02277184",
      "title": "Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Ficlatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity Modulated Radiotherapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Julie E. Bauman, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-09",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 3,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277184"
    },
    {
      "nct_id": "NCT00548548",
      "title": "A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 774,
      "start_date": "2007-09",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00548548"
    },
    {
      "nct_id": "NCT01399372",
      "title": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapeutic Agent Toxicity",
        "Cognitive/Functional Effects",
        "Lymphoma",
        "Neurotoxicity",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Procarbazine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "low-dose whole-brain radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2011-09",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399372"
    },
    {
      "nct_id": "NCT03560349",
      "title": "RCT of SPG Blocks for Post-dural Headache",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Dural Puncture Headache"
      ],
      "interventions": [
        {
          "name": "Lidocaine HCl Gel 2%",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-01",
      "completion_date": "2019-01-01",
      "has_results": false,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03560349"
    },
    {
      "nct_id": "NCT06023641",
      "title": "Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dactinomycin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Surgical Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Proton beam radiation or external beam radiation or brachytherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Liposomal irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim, peg-filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "Up to 22 Years"
      },
      "enrollment_count": 135,
      "start_date": "2024-03-13",
      "completion_date": "2037-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06023641"
    },
    {
      "nct_id": "NCT00774202",
      "title": "Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Rituxan, Cyclophosphamide, Vincristine, Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Higher Dose of Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 17,
      "start_date": "2003-11",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774202"
    },
    {
      "nct_id": "NCT01693718",
      "title": "A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "5- Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "59 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "59 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2003-03",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2024-01-29",
      "last_synced_at": "2026-09-02T11:20:10.606Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693718"
    }
  ]
}